Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, et al.
Pharmacological Research (2023) Vol. 188, pp. 106659-106659
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies
Bo Zhao, Xinrong Hu, Weidong Wang, et al.
Acta Pharmacologica Sinica (2025)
Closed Access | Times Cited: 3
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry
Pasquale Paolisso, Luca Bergamaschi, Arturo Cesaro, et al.
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110766-110766
Closed Access | Times Cited: 40
Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy
Aneta Čináková, Diana Vavrincová-Yaghi, Peter Křenek, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Contrast-Induced Acute Kidney Injury in Patients with Heart Failure on Sodium–Glucose Cotransporter-2 Inhibitors Undergoing Radiocontrast Agent Invasive Procedures: A Propensity-Matched Analysis
Giulia Nardi, Enrico Marchi, Marco Allinovi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2041-2041
Open Access | Times Cited: 5
RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2
Jiangjun Wei, Fangyan Tan, Xianglin Long, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 189, pp. 106531-106531
Open Access | Times Cited: 13
Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side
Aly M. Abdelrahman, Alaa S. Awad, Emaad M. Abdel‐Rahman
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 956-956
Open Access | Times Cited: 4
Unraveling Chronic Cardiovascular and Kidney Disorder through the Butterfly Effect
Dimitri Bedo, Thomas Beaudrey, Nans Florens
Diagnostics (2024) Vol. 14, Iss. 5, pp. 463-463
Open Access | Times Cited: 4
Repurposing Secukinumab and Dapagliflozin as Candidate Therapies to Mitigate the Renal Toxicity of Sunitinib in Rats Through Suppressing IL‐17‐Mediated Pyroptosis and Promoting Autophagy
Rania A. Elrashidy, Hoda E. Mohamad, Sara M. Abdel Aal, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 3
Closed Access
Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
Tapan Patel, Hong Zheng, Kaushik P. Patel
Antioxidants (2025) Vol. 14, Iss. 3, pp. 336-336
Open Access
SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure
Elena Conte, Paola Imbrici, Giorgia Dinoi, et al.
European Journal of Pharmacology (2025), pp. 177617-177617
Open Access
Global trends and disparities in the burden of heart failure caused by chronic kidney disease: an analysis of the global burden of disease study 2021
Lingxia Ye, Xin Huang, Yufeng Xu
Frontiers in Medicine (2025) Vol. 12
Open Access
Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
Giovanna Castoldi, Raffaella Carletti, Francesca Barzaghi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 362-362
Open Access | Times Cited: 3
Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet
Silvie Hojná, Hana Malínská, Martina Hüttl, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116520-116520
Open Access | Times Cited: 3
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Endothelial Dysfunction and Heart Failure with Preserved Ejection Fraction—An Updated Review of the Literature
Mariarosaria De Luca, Giulia Crisci, Giuseppe Armentaro, et al.
Life (2023) Vol. 14, Iss. 1, pp. 30-30
Open Access | Times Cited: 7
Emodin alleviates CRS4‐induced mitochondrial damage via activation of the PGC1α signaling
Xin Dong, Ruijia Wen, Yuanyuan Xiong, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 3, pp. 1345-1357
Closed Access | Times Cited: 2
Protective effects and mechanisms of dapagliflozin on renal ischemia/reperfusion injury
Qiuxiao-Zhu, Huiyao-Hao, Na Li, et al.
Transplant Immunology (2024) Vol. 84, pp. 102010-102010
Closed Access | Times Cited: 2
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Effects of sacubitril-valsartan on aging-related cardiac dysfunction
Marialucia Telesca, Antonella De Angelis, Maria Donniacuo, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176794-176794
Open Access | Times Cited: 2
A novel model of cardiovascular–kidney–metabolic syndrome combining unilateral nephrectomy and high-salt–sugar–fat diet in mice
Lucas Rannier Ribeiro Antonino Carvalho, Miho Shimari, Ariela Maína Boeder, et al.
Lab Animal (2024) Vol. 53, Iss. 11, pp. 336-346
Open Access | Times Cited: 2
Association between a high triglyceride–glucose index and chronic kidney disease in adult patients with latent autoimmune diabetes
Xiuli Fu, Zihui Xu, Qin Tan, et al.
BMC Endocrine Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Effects of empagliflozin on right ventricular adaptation to pressure overload
Julie Birkmose Axelsen, Anders Hammer Nielsen-Kudsk, Janne Schwab, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Jia Liu, Xiaona Chang, Xiaoyu Ding, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Sodium Glucose Co-transporter 2 Inhibitors: Pharmacology, Mechanism of Action and Efficacy in Non-diabetic Kidney Disease from Bench to Bed-Side
Aly M. Abdelrahman, Alaa S. Awad, Emaad M. Abdel‐Rahman
(2024)
Open Access | Times Cited: 1
Effect of dapagliflozin on oxidative stress in heart embryonic H9c2 cardiomyocytes
Zeki Doğan
International journal of medical biochemistry/International journal of medical biochemistry : (2024), pp. 6-12
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top